IPO Journey
Alamar Biosciences, Inc.
IPO Date: April 17, 2026 · 4 filings tracked
Final Offer Terms
Ticker
ALMR
Exchange
The Nasdaq Global Select Market
Offer Price
$17.00
Shares Offered
11,250,000
Estimated Proceeds
$191.3M
Underwriters
Led by J.P. Morgan, BofA Securities
TD CowenLeerink PartnersStifel
Filing Timeline
1
S-1
March 27, 2026
- Proprietary NULISA technology enables ultra-sensitive protein detection for early disease diagnosis.
- High-growth 'razor-and-blade' business model with recurring revenue from chemical kits.
2
S-1/A
April 13, 2026
- Proprietary NULISA technology enables ultra-sensitive protein detection for early disease diagnosis.
- High-growth 'razor-and-blade' business model with recurring revenue from chemical test kits.
Changes from previous filing
- ▸ Exchange: The Nasdaq Global Select Market
- ▸ Expected offer range: $15.0 – $17.0 per share
- ▸ Shares offered: 9,375,000
- ▸ Estimated proceeds: $140M
3
S-1/A
April 16, 2026
- Rapid revenue growth, nearly tripling from $25.1M in 2024 to $74.2M in 2025.
- High-adoption 'razor and blade' model with installed base growth from 36 to 102 machines.
424B4
Final Pricing
April 17, 2026
- Proprietary NULISA technology enables ultra-sensitive protein detection for early disease diagnosis.
- Strong recurring revenue model driven by high-margin chemical kit consumables.
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $17.0 per share
- ▸ Shares offered: 11,250,000
- ▸ Estimated proceeds: $191M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.